Kailera Therapeutics Debut Marks Largest Biotech IPO Since 2021 Amid Weight Loss Race

Kailera Therapeutics prices $625 million IPO, advances GLP-1 obesity pipeline as trial data highlights oral ribupatide weight loss results. Importance Rank: 1 read more

Go to News Site